ArticleJournal of oncology practice2016
Improving the Safety of Oral Chemotherapy at an Academic Medical Center.
Article in Journal of oncology practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Effectiveness of a nurse-led telephone follow-up in the therapeutic management of patients receiving oral antineoplastic agents: a randomized, multicenter controlled trial (ETICCO study).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Trial
- Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Trial
- Investigating Real-World Tolerance and Dose Reductions of Oncology Multikinase Inhibitors in a VA Population.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2026Article
- Impact of VA Hematology/Oncology Clinical Pharmacy Practitioners in the Review of Community Prescriptions for Specialty Medications.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2024Article
- Clinical Pharmacy Initiatives Contribute to the Excellent Efficacy of the Dabrafenib/Trametinib Combination for Iodine-Refractory Thyroid Carcinoma: A Case Report.Medicina (Kaunas, Lithuania) · 2024Article
- Enhancing Hospital Pharmacy Operations Through Lean and Six Sigma Strategies: A Systematic Review.Cureus · 2024Review
- Lean Healthcare Tools for Processes Evaluation: An Integrative Review.International journal of environmental research and public health · 2021Review
- The Expanding Role of the Oncology Pharmacist.Pharmacy (Basel, Switzerland) · 2020Article
- Improvement in adherence to Capecitabine and Lapatinib by way of a therapeutic education program.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Cetuximab Conjugated with Octreotide and Entrapped Calcium Alginate-beads for Targeting Somatostatin Receptors.Scientific reports · 2020Article
- Financial impact of oral chemotherapy wastage on society and the patient.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2019Article
- 2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard.Journal of oncology practice · 2019Article
- Applying lean methodology to improve parenteral chemotherapy and monoclonal antibody documentation processes based on Normalisation Process Theory.European journal of hospital pharmacy : science and practice · 2018Article
- Usefulness of a pharmacist outpatient service for S-1 adjuvant chemotherapy in patients with gastric cancer.Molecular and clinical oncology · 2017Article
- Multidisciplinary Optimization of Oral Chemotherapy Delivery at the University of Wisconsin Carbone Cancer Center.Journal of oncology practice · 2016Article
- Medication errors and shift to a culture of patient safety and high reliability.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
purposeOver the last decade, the use of oral chemotherapy (OC) for the treatment of cancer has dramatically increased. Despite their route of administration, OCs pose many of the same risks as intravenous agents. In this quality improvement project, we sought to examine our current process for the prescription of OC at the Abramson Cancer Center of the University of Pennsylvania and to improve on its safety.
methodsA multidisciplinary team that included oncologists, advanced-practice providers, and pharmacists was formed to analyze the current state of our OC practice. Using Lean Six Sigma quality improvement tools, we identified a lack of pharmacist review of the OC prescription as an area for improvement. To address these deficiencies, we used our electronic medical system to route OC orders placed by treating providers to an oncology-specific outpatient pharmacist at the Abramson Cancer Center for review.
resultsOver 7 months, 63 orders for OC were placed for 45 individual patients. Of the 63 orders, all were reviewed by pharmacists, and, as a result, 22 interventions were made (35%). Types of interventions included dosage adjustment (one of 22), identification of an interacting drug (nine of 22), and recommendations for additional drug monitoring (12 of 22).
conclusionOC poses many of the same risks as intravenous chemotherapy and should be prescribed and reviewed with the same oversight. At our institution, involvement of an oncology-trained pharmacist in the review of OC led to meaningful interventions in one third of the orders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.